The human gastrointestinal (GI) tract microbiome is a complex and all-encompassing ecological system of trillions of microorganisms. It plays a vital role in digestion, disease prevention, and overall health. When this delicate balance is disrupted, it can lead to various health issues. Fecal microbiota transplantation (FMT) is an emerging therapeutic intervention used as an adjuvant therapy for many diseases, particularly those with dysbiosis as their underlying cause. Its goal is to restore this balance by transferring fecal material from healthy donors to the recipients. FMT has an impressive reported cure rate between 80% and 90% and has become a favored treatment for many diseases. While FMT may have generally mild to moderate transient adverse effects, rare severe complications underscore the importance of rigorous donor screening and standardized administration. FMT has enormous potential as a practical therapeutic approach; however, additional research is required to further determine its potential for clinical utilization, as well as its safety and efficiency in different patient populations. This comprehensive literature review offers increased confidence in the safety and effectiveness of FMT for several diseases affecting the intestines and other systems, including diabetes, obesity, inflammatory and autoimmune illness, and other conditions.

Colorectal cancer (CRC) remains one of the most common causes of cancer-related mortality worldwide. Its progression is influenced by complex interactions involving genetic, epigenetic, and environmental factors. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have been identified as key regulators of gene expression, affecting diverse biological processes, notably programmed cell death (PCD). This review aims to explore the relationship between ncRNAs and PCD in CRC, focusing on how ncRNAs influence cancer cell survival, proliferation, and treatment resistance. A comprehensive literature analysis was conducted to examine recent findings on the role of ncRNAs in modulating various PCD mechanisms, including apoptosis, autophagy, necroptosis, and pyroptosis, and their impact on CRC development and therapeutic response. ncRNAs were found to significantly regulate PCD pathways, impacting tumor growth, metastasis, and treatment sensitivity in CRC. Their influence on these pathways highlights the potential of ncRNAs as biomarkers for early CRC detection and as targets for innovative therapeutic interventions. Understanding the involvement of ncRNAs in PCD regulation offers new insights into CRC biology. The targeted modulation of ncRNA-PCD interactions presents promising avenues for personalized cancer treatment, which may improve patient outcomes by enhancing therapeutic effectiveness and reducing resistance.

Probiotic and synbiotic supplementation has garnered attention for its potential to modulate metabolic parameters, including glycemic control, in individuals with prediabetes and type 2 diabetes mellitus (T2DM). This systematic review and dose-response meta-analysis aims to evaluate the effectiveness of these supplements on glycemic indices, synthesizing evidence from randomized controlled trials (RCTs) with grade-assessed methodologies. A comprehensive search of scientific databases was conducted from inception through January 2025 to identify RCTs assessing the effects of probiotic and synbiotic supplementation on glycemic indices, including fasting blood glucose (FBG), fasting insulin (FI), hemoglobin A1c (HbA1c), and homeostatic model assessment for insulin resistance (HOMA-IR). Eligible studies were screened; relevant data were extracted, and the quality of evidence was evaluated using the GRADE approach. Statistical analyses were performed using STATA to generate pooled results. The pooled analysis of 48 RCTs demonstrated that probiotics and synbiotics supplementation significantly decreased FBG (WMD: - 7.00 mg/dL), FI (WMD: - 1.72 µIU/mL), HbA1c levels (WMD: - 0.34%), and HOMA-IR (WMD: - 0.91), with a substantial heterogeneity across all outcomes (p < 0.001). Subgroup analyses indicated reductions in FBG, FI, HbA1c, and HOMA-IR across varying baseline characteristics, including glycemic levels, trial durations, and participant health status. Both probiotics and synbiotics were effective, with notable benefits for patients with T2DM, longer intervention durations, and higher baseline BMI. Meta-regression and dose-response analyses revealed no significant association between the duration of probiotic and synbiotic supplementation and changes in glycemic indices. Probiotic and synbiotic supplements significantly reduce FBG, FI, HbA1c, and HOMA-IR, leading to improvements in glycemic markers in individuals with prediabetes and T2DM. These supplements can be used as effective adjunctive strategies to enhance glycemic control, highlighting the promising role of gut microbiota modulation in diabetes management.

Background: Obesity is a significant public health issue associated with various chronic diseases. Research has indicated that chia seeds have the potential to improve cardiometabolic health. However, due to the diversity of research and inconsistencies in study design, further investigation is needed to fully understand their clinical effects on overweight individuals. This review aims to comprehensively analyze the available evidence on the effects of chia seeds on cardiometabolic indices in overweight populations through a meta-analysis. Methods: A comprehensive literature search was performed across PubMed, Web of Science, Scopus, and Embase databases from their inception until 01-03-2024 to identify randomized controlled trials (RCTs) evaluating the effect of chia on cardiometabolic indices in overweight subjects. The search strategy incorporated both Medical Subject Headings (MeSH). Following the screening, ten RCTs were finally included. The data, including subject characteristics, study design, and changes in serum biomarkers, were extracted and analyzed using Stata software version 18. Results: The meta-analysis results reveal that chia supplementation no significant changes in lipid profile, including triglycerides (TG) (MD: − 5.80 mg/dL, p = 0.47), total cholesterol (TC) (MD: − 0.29 mg/dL, p = 0.95), high-density lipoprotein (HDL) (MD: 1.53 mg/dL, p = 0.33), and low-density lipoprotein (LDL) (MD: 0.63 mg/dL, p = 0.88). Similarity fasting blood glucose (FBG) (MD: − 0.03 mg/dL, p = 0.98), hemoglobin A1c (HbA1c) (MD: − 0.13%, p = 0.13), and insulin levels (MD: 0.45 µIU/mL, p = 0.78). However, chia seed supplementation was associated with a significant reduction in C-reactive protein (CRP) (MD: − 1.18 mg/L, p < 0.0001), but no significant changes were observed in interleukin-6 (IL-6) (MD: − 0.15, p = 0.70) or tumor necrosis factor-alpha (TNF-α) (MD: 0.03, p = 0.91). There was no significant effect on body mass index (BMI) (MD: 0.1 kg/m ² , p = 0.91), but a significant reduction in waist circumference (WC) (MD: − 2.82 cm, p < 0.001) was noted. Additionally, chia seed supplementation resulted in a significant reduction in systolic blood pressure (BP) (MD: − 3.27 mmHg, p = 0.03), though diastolic BP changes were non-significant (MD: − 2.69 mmHg, p = 0.09). The studies showed low to moderate heterogeneity in outcome measures, with I ² < 50%. Conclusion: Chia seed supplementation does not significantly impact most lipid profile parameters and glycemic markers. However, it shows potential benefits in reducing WC, BP, and CRP. While chia seeds can be a valuable addition to cardiometabolic health management, they should be part of a broader health strategy that includes a balanced diet, exercise, and lifestyle modifications for optimal results.

Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are a pair of relatively modern therapeutic surgical methods in advanced cancerous patients with peritoneal metastasis (PM). The goal of CRS + HIPEC is treatment or to improve survival outcomes, which are linked to high morbidity side effects and complications, even with their possible advantages. Surgical-related, chemotherapy-related, anesthetic-related, gastrointestinal, organs and systemic complications are the categories into which complications are separated according to frequency, risk factors, and effect on patient outcomes. In this narrative review of the literature, the side effects and complications of HIPEC + CRS in cancer patients with PM are examined. The present knowledge on the incidence, frequency, kinds, and risk factors of acute complications following CRS + HIPEC is summarized in this study. This review emphasizes the need for careful patient selection criteria, precise surgical technique, and thorough intraoperative care to reduce or manage these risks. Moreover, it highlights the need for interdisciplinary collaboration in treating these patients. This study aims to know these complications, improve clinical practice, and guide future studies to increase the safety and efficacy of CRS + HIPEC in treating metastatic colorectal cancer.

Background and Aim: The Mediterranean diet (MD) is widely recognized for its health benefits and potential protective effects against various chronic diseases such as cardiovascular conditions and cancer. This meta‐analysis evaluates the association between MD adherence and breast cancer risk in women.Methods: A comprehensive search of major databases was conducted until November 2024 to identify cohort or case‐control studies. The meta‐analysis employed a random‐effects model to pool multivariable‐adjusted effect sizes, reporting them as hazard ratios (HR) while evaluating heterogeneity using the I² statistic and assessing publication bias.Results: The pooled analysis of 31 studies indicated a significant association between adherence to the MD and a 13% risk reduction in risk of breast cancer (HR: 0.87, 95% CI: 0.82–0.92; I² = 70%). Specifically, postmenopausal women exhibited a 12% significant reduction in the risk of breast cancer (HR: 0.88; 95% CI: 0.84, 0.92), while premenopausal women showed no significant effect (HR: 0.98, 95% CI: 0.90, 1.06). Geographically, the effect was most pronounced in Asia (OR: 0.59, 95% CI: 0.50, 0.68), while from America (OR: 0.92, 95% CI: 0.82, 1.02) and Europe (OR: 0.90, 95% CI: 0.83, 0.97) showed moderate associations. Subgroup analysis suggested a stronger significant association in case‐control studies (HR: 0.77, 95% CI: 0.70, 0.85), whereas no significant association was observed in cohort studies (HR: 0.96, 95% CI: 0.90, 1.02).Conclusion: Adherence to the Mediterranean diet is associated with a significant reduction in breast cancer risk, particularly among postmenopausal women and in regions such as Asia. These findings suggest that the Mediterranean diet may be an important dietary factor in reducing breast cancer risk, especially in certain populations. However, further research is needed to confirm its impact in different study designs and geographical areas.